These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104. hTERT promoter methylation promotes small cell lung cancer progression and radiotherapy resistance. Zhai G; Li J; Zheng J; An P; Chen X; Wang X; Li C J Radiat Res; 2020 Sep; 61(5):674-683. PubMed ID: 32761059 [TBL] [Abstract][Full Text] [Related]
105. TCGA Pan-Cancer Genomic Analysis of Alternative Lengthening of Telomeres (ALT) Related Genes. Armendáriz-Castillo I; López-Cortés A; García-Cárdenas J; Guevara-Ramírez P; Leone PE; Pérez-Villa A; Yumiceba V; Zambrano AK; Guerrero S; Paz-Y-Miño C Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32708340 [TBL] [Abstract][Full Text] [Related]
106. The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic Implications. Recagni M; Bidzinska J; Zaffaroni N; Folini M Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290440 [TBL] [Abstract][Full Text] [Related]
107. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells. Cimino-Reale G; Gandellini P; Santambrogio F; Recagni M; Zaffaroni N; Folini M J Hematol Oncol; 2017 Jul; 10(1):140. PubMed ID: 28716051 [TBL] [Abstract][Full Text] [Related]
108. Alternative lengthening of telomeres (ALT) and chromatin: is there a connection? Nittis T; Guittat L; Stewart SA Biochimie; 2008 Jan; 90(1):5-12. PubMed ID: 17935854 [TBL] [Abstract][Full Text] [Related]
109. Inhibition of telomerase induces alternative lengthening of telomeres during human esophageal carcinogenesis. Queisser A; Heeg S; Thaler M; von Werder A; Opitz OG Cancer Genet; 2013 Nov; 206(11):374-86. PubMed ID: 24331919 [TBL] [Abstract][Full Text] [Related]
110. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT). De Vitis M; Berardinelli F; Sgura A Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031 [TBL] [Abstract][Full Text] [Related]
111. Alternative Lengthening of Telomeres in the Budding Yeast Cohn M; Andersson AK; Mateo RQ; Möller MC G3 (Bethesda); 2019 Oct; 9(10):3345-3358. PubMed ID: 31427453 [TBL] [Abstract][Full Text] [Related]
112. Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. Relitti N; Saraswati AP; Federico S; Khan T; Brindisi M; Zisterer D; Brogi S; Gemma S; Butini S; Campiani G Curr Top Med Chem; 2020; 20(6):433-457. PubMed ID: 31894749 [TBL] [Abstract][Full Text] [Related]
113. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Yuan X; Larsson C; Xu D Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550 [TBL] [Abstract][Full Text] [Related]
114. In perspective: An update on telomere targeting in cancer. Sugarman ET; Zhang G; Shay JW Mol Carcinog; 2019 Sep; 58(9):1581-1588. PubMed ID: 31062416 [TBL] [Abstract][Full Text] [Related]